{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:37:06Z","timestamp":1791247026137,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":216,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220680"],"award-info":[{"award-number":["20220680"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220680"],"award-info":[{"award-number":["20220680"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Whether a history of malignancy affects heart failure (HF) management and prognosis is unclear. In HF randomized controlled trials, enrolment has been limited to patients with a cancer diagnosis at least 2\u2009years before screening. We investigated clinical profile, HF treatment patterns, and outcomes of patients with a history of cancer of &amp;gt;2\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Among 53\u2009314 patients included in the Swedish HF Registry between 2000 and 2020, 9066 (17%) had previous cancer (diagnosed &amp;gt;2\u2009years prior to index date), most frequently of prostate (26%), breast (15%), colon (11%), and haematologic system (11%). Previous cancer was associated with older age, female sex, comorbidity burden, and less likely specialized follow-up. Over a median follow-up of 2.4 (0.0\u20135.0) years, mortality rates were 24 (95% confidence interval [CI] 23\u201325) and 18 (95% CI 18\u201319) per 100 subject-years in patients with versus without previous cancer, respectively. Cancer accounted for 16% of deaths in the previous cancer group and for 5.6% in the no-cancer group. Previous cancer was independently associated with higher risk of all-cause death (adjusted hazard ratio [HR] 1.14, 95% CI 1.11\u20131.18), non-cardiovascular death (adjusted HR 1.38, 95% CI 1.31\u20131.44), and first all-cause hospitalization (adjusted HR 1.11, 95% CI 1.09\u20131.14). The risk of non-cardiovascular death declined with increasing time from cancer diagnosis. In patients with HF and reduced ejection fraction (HFrEF), previous cancer was associated with less frequent use of mineralocorticoid receptor antagonists, triple pharmacotherapy, and HF devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Previous cancer was common among patients with HF, and it was associated with comorbidity burden, non-cardiovascular outcomes and, in HFrEF, with lower use of guideline-recommended therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3775","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T13:49:21Z","timestamp":1752760161000},"page":"2116-2129","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Characteristics and Outcomes of Patients with Heart Failure and History of Malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register"],"prefix":"10.1093","volume":"27","author":[{"given":"Pietro","family":"Ameri","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]},{"name":"Cardiac, Thoracic, and Vascular Department, IRCCS Ospedale Policlinico San Martino , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Genoa ,","place":["Italy"]},{"name":"Department of Clinical Sciences and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Benson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Stolfo","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]},{"name":"Cardiothoracic Department, University Hospital Santa Maria della Misericordia, ASUFC , Udine ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil V.","family":"Sayour","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"Gottsegen National Cadiovascular Center , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Ljungman","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg , Goteborg ,","place":["Sweden"]},{"name":"Department of Cardiology, Sahlgrenska University Hospital , Goteborg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Baylor College of Medicine , Houston, TX ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Campus Virchow Klinikum , Berlin ,","place":["Germany"]},{"name":"Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigation Clinique-Plurith\u00e9matique CIC-P 1433, Inserm U1116, CHRU Nancy Brabois , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Keramida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, General Anti-Cancer Oncological Hospital Agios Savvas , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Education, S\u00f6dersjukhuset, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"2026021721500512400_ejhf3775-bib-0001","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/S2666-7568(24)00108-9","article-title":"The economic burden of cancer, coronary heart disease, dementia, and stroke in England in 2018, with projection to 2050: An evaluation of two cohort studies","volume":"5","author":"Landeiro","year":"2024","journal-title":"Lancet Health Longev"},{"key":"2026021721500512400_ejhf3775-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0003","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ejhf.3506","article-title":"Trends in heart failure mortality in Sweden between 1997 and 2022","volume":"27","author":"Lindberg","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0004","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ejhf.1569","article-title":"Trends in modes of death in heart failure over the last two decades: Less sudden death but cancer deaths on the rise","volume":"21","author":"Moliner","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.hlc.2024.03.008","article-title":"Guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and incident cancer","volume":"33","author":"Tini","year":"2024","journal-title":"Heart Lung Circ"},{"key":"2026021721500512400_ejhf3775-bib-0006","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026021721500512400_ejhf3775-bib-0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/cer.15.27","article-title":"Should criteria for inclusion in cancer clinical trials be expanded?","volume":"4","author":"Gerber","year":"2015","journal-title":"J Comp Eff Res"},{"key":"2026021721500512400_ejhf3775-bib-0008","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2018.2559","article-title":"Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: A systematic review","volume":"3","author":"Tahhan","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: A living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2026021721500512400_ejhf3775-bib-0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026021721500512400_ejhf3775-bib-0011","volume-title":"MEB Guideline: The Swedish Cancer Register","year":"2007"},{"key":"2026021721500512400_ejhf3775-bib-0012","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1186\/s12885-021-08481-5","article-title":"Diagnostic codes of cancer in Sk\u00e5ne healthcare register: A validation study using individual-level data in southern Sweden","volume":"21","author":"Shen","year":"2021","journal-title":"BMC Cancer"},{"key":"2026021721500512400_ejhf3775-bib-0013","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721500512400_ejhf3775-bib-0014","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721500512400_ejhf3775-bib-0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026021721500512400_ejhf3775-bib-0016","volume-title":"Flexible multivariate imputation by MICE","author":"Oudshoorn","year":"1999"},{"key":"2026021721500512400_ejhf3775-bib-0017","first-page":"8","article-title":"Cancer incidence and mortality in patients diagnosed with heart failure: Results from an updated systematic review and meta-analysis","volume":"9","author":"Camilli","year":"2023","journal-title":"Cardiooncology"},{"key":"2026021721500512400_ejhf3775-bib-0018","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.472","article-title":"Incidence of cancer in patients with chronic heart failure: A long-term follow-up study","volume":"18","author":"Banke","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0019","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","article-title":"Heart failure after myocardial infarction is associated with increased risk of cancer","volume":"68","author":"Hasin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jjcc.2020.07.026","article-title":"Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study","volume":"77","author":"Kwak","year":"2021","journal-title":"J Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2020.05.035","article-title":"Prevalence and incidence of various cancer subtypes in patients with heart failure vs matched controls","volume":"316","author":"Schwartz","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0022","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jacc.2011.11.040","article-title":"Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction","volume":"59","author":"Ather","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0023","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jchf.2023.06.011","article-title":"Noncardiac comorbidities in chronic heart failure: More is worse, what else do we know?","volume":"11","author":"Mentz","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0024","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ejhf.2818","article-title":"Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials","volume":"25","author":"Dobbin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0025","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ejhf.2207","article-title":"The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative","volume":"23","author":"Leedy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0026","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jacc.2018.01.069","article-title":"Lack of association between heart failure and incident cancer","volume":"71","author":"Selvaraj","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0027","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ejhf.1252","article-title":"Cancer and heart failure-more than meets the eye: Common risk factors and co-morbidities","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0028","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"2026021721500512400_ejhf3775-bib-0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026021721500512400_ejhf3775-bib-0030","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"2026021721500512400_ejhf3775-bib-0031","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehac710","article-title":"Cancer is a comorbidity of heart failure","volume":"44","author":"Ameri","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721500512400_ejhf3775-bib-0032","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0033","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ehf2.13848","article-title":"Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure","volume":"9","author":"Lindberg","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026021721500512400_ejhf3775-bib-0034","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"key":"2026021721500512400_ejhf3775-bib-0035","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180390","article-title":"Review of risk factors of secondary cancers among cancer survivors","volume":"92","author":"Demoor-Goldschmidt","year":"2019","journal-title":"Br J Radiol"},{"key":"2026021721500512400_ejhf3775-bib-0036","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review","volume":"13","author":"Shalata","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026021721500512400_ejhf3775-bib-0037","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cger.2015.08.005","article-title":"Long-term toxicity of cancer treatment in older patients","volume":"32","author":"Shahrokni","year":"2016","journal-title":"Clin Geriatr Med"},{"key":"2026021721500512400_ejhf3775-bib-0038","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016309","article-title":"Cancer mortality in trials of heart failure with reduced ejection fraction: A systematic review and meta-analysis","volume":"9","author":"Tini","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026021721500512400_ejhf3775-bib-0039","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721500512400_ejhf3775-bib-0040","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/eurheartj\/ehae105","article-title":"Heart failure pharmacotherapy and cancer: Pathways and pre-clinical\/clinical evidence","volume":"45","author":"Sayour","year":"2024","journal-title":"Eur Heart J"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2116\/66833579\/eurjhf_27_11_2116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2116\/66833579\/eurjhf_27_11_2116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:50:17Z","timestamp":1771383017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2116\/8470323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,17]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3775","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"2025-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}